Elara Capital has initiated coverage on UGRO Capital with a Buy rating and a target price of ₹226, based on 1.2x FY27E book ...
SOL-1 Phase 3 superiority trial results remain masked to date SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting Ocular plans to submit NDA for AXPAXLI™ in wet AMD based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results